Alkermes to Report Third Quarter Financial Results on October 28, 2025

Rhea-AI Summary

Alkermes (Nasdaq: ALKS) will report third quarter 2025 financial results and host a conference call and webcast on Oct 28, 2025 at 8:00 a.m. ET (12:00 p.m. GMT). The event will include slides available on the company's Investors website and a replay posted about two hours after the event.

Live access: U.S. dial +1 877 407 2988; international dial +1 201 389 0923. Alkermes is a global biopharmaceutical company focused on neuroscience with marketed products for alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline including narcolepsy and idiopathic hypersomnia. Headquarters in Ireland with R&D in Massachusetts and manufacturing in Ohio.

News Market Reaction – ALKS

+1.52%

+1.52% Session close to close

In the Oct 21 session, ALKS gained 1.52%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DUBLIN, Oct. 20, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (12:00 p.m. GMT) on Tuesday, Oct. 28, 2025 to discuss the company's third quarter financial results.

The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the event and may be accessed by visiting Alkermes' website. 

About Alkermes plc

Alkermes plc (Nasdaq: ALKS), a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

Alkermes Contact:
Jamie Constantine
Investor Relations
+1 781 873 2402

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-to-report-third-quarter-financial-results-on-october-28-2025-302589282.html

SOURCE Alkermes plc

FAQ

When will Alkermes (ALKS) report third quarter 2025 results and when is the conference call?

Alkermes will report Q3 2025 results and hold a conference call and webcast on Oct 28, 2025 at 8:00 a.m. ET.

How can investors access the Alkermes (ALKS) Oct 28, 2025 webcast and slides?

The webcast player and accompanying slides will be available on the Investors section of alkermes.com.

What are the dial-in numbers for the Alkermes (ALKS) Oct 28, 2025 conference call?

U.S. callers: +1 877 407 2988; international callers: +1 201 389 0923.

Will a replay be available after the Alkermes (ALKS) Oct 28, 2025 call and when?

Yes. A replay of the webcast will be available approximately two hours after the event on Alkermes' website.

What therapeutic areas and products does Alkermes (ALKS) highlight in its company description?

Alkermes focuses on neuroscience with marketed products for alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder.

Where are Alkermes (ALKS) headquarters and key facilities located?

Alkermes is headquartered in Ireland with an R&D center in Massachusetts and a manufacturing facility in Ohio.